OA-SYS / Ageless Biotech - LARVOL DELTA

OA-SYS-01: An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Trial completion date: May 2028 ➔ Dec 2028 | Initiation date: Jan 2025 ➔ Apr 2025

Trial completion date • Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology

OA-SYS-01: An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Initiation date: Oct 2024 ➔ Jan 2025

Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology

OA-SYS-01: A Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

OA-SYS-01: A Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: Ageless Biomed, Inc

New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology

Ageless Biotech Engages Board of Director for United States MMA Federation as Principal Investigator for FDA Investigational New Drug (IND) Phase II Trial (PRNewswire) - "Ageless Biotech...is proud to have Board Certified Orthopedic Surgeon Dr. Randa Bascharon as a Principal Investigator for Ageless Biotech's U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee."

IND • CNS Disorders • Osteoarthritis • Pain